Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 9/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357615 | 1.00 | NOS1 (0.55) | NOS1HSD17B10KDM4EALDH1A1THRB | |
| SCHEMBL7683616 | 0.87 | AKR1B1 (0.57) | NOS1HSD17B10KDM4EALDH1A1THRB | |
| SCHEMBL23028966 | 0.83 | NOS1 (0.53) | NOS1HSD17B10KDM4EALDH1A1THRB | |
| SCHEMBL24811788 | 0.80 | NOS1 (0.60) | NOS1HSD17B10KDM4EALDH1A1THRB | |
| SCHEMBL853171 | 0.77 | NOS1 (0.60) | NOS1HSD17B10KDM4EALDH1A1THRB | |
| SCHEMBL22497885 | 0.77 | NOS1 (0.57) | NOS1HSD17B10KDM4EALDH1A1THRB | |
| SCHEMBL3528801 | 0.77 | NOS1 (0.57) | NOS1HSD17B10KDM4EALDH1A1THRB | |
| SCHEMBL3526051 | 0.77 | NOS1 (0.57) | NOS1HSD17B10KDM4EALDH1A1THRB | |
| SCHEMBL3528782 | 0.77 | NOS1 (0.57) | NOS1HSD17B10KDM4EALDH1A1THRB | |
| SCHEMBL398502 | 0.74 | KDM4E (0.38) | NOS1HSD17B10KDM4EALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3641802-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS WITH AGENTS CAPABLE OF INHIBITING THE ACTIVATION OF MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS | INST NAT SANTE RECH MED (FR) | 2026-05-13 | — | — | EP | claimed |
| US-20260069594-A1 | USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | INST NAT SANTE RECH MED (FR) | 2026-03-12 | — | — | US | claimed |
| CN-118191182-A | HPLC detection method for 6-formylpterin in folic acid | 河北冀衡药业股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2024047196-A1 | USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| CN-113125611-B | Method for detecting content of impurity 6-formyl pterin folic acid | 北京斯利安药业有限公司 | 2023-04-18 | — | — | CN | claimed |
| US-20220184083-A1 | USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-06-16 | — | — | US | claimed |
| EP-3941448-A1 | USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-01-26 | — | — | EP | claimed |
| US-20210403573-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS WITH AGENTS CAPABLE OF INHIBITING THE ACTIVATION OF MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS | UNIVERSITÉ PARIS CITÉ (FR) | 2021-12-30 | — | — | US | claimed |
| CN-113125611-A | Method for detecting content of impurity 6-formyl pterin folic acid | 北京斯利安药业有限公司 | 2021-07-16 | — | — | CN | claimed |
| WO-2020187955-A1 | USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-09-24 | — | — | WO | claimed |
| US-20050239807-A1 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-27 | — | — | US | claimed |
| US-6861514-B2 | Nucleosidic and non-nucleosidic folate conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-01 | — | — | US | claimed |
| CN-1084332-C | Active oxygen scavenger containing pterin derivative | CMIC CO LTD (JP) | 2002-05-08 | — | — | CN | claimed |
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | ISIS PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | claimed |
| US-6162806-A | Active oxygen scavengers containing pterin derivatives | ARTEMIS, INC. (JP) | 2000-12-19 | — | — | US | claimed |
| WO-1999066063-A9 | NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 2000-06-08 | — | — | WO | claimed |
| WO-1999066063-A2 | NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-23 | — | — | WO | claimed |
| EP-0884317-A2 | ACTIVE OXYGEN SCAVENGERS CONTAINING PTERIN DERIVATIVES | Artemis Inc. (JP) | 1998-12-16 | — | — | EP | claimed |
| CN-1198161-A | Active oxygen scavengers containing pterin derivatives | ARTEMIS INC (JP) | 1998-11-04 | — | — | CN | claimed |
| US-4326060-A | 6-FORMYLPTERIN, P-AMINOBENZOYL AMINO ACID | BAKER INSTRUMENTS CORPORATION (US) | 1982-04-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | MTHFD1, DHFR, FOLR1 | NOS1 2254/4885HSD17B10 1673/4885KDM4E 3493/4885 |
| US-20050239807-A1 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | NOS1, SOD1, NOS3 | NOS1 1/4885HSD17B10 1842/4885KDM4E 4425/4885 |
| US-20260069594-A1 | USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | MIF, MTX1, PTGS1 | NOS1 237/4885HSD17B10 2201/4885KDM4E 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.